Yurii Ostapenko
National Cancer Institute · 13 works · 1,049 citations · h-index 6
Top works
- Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
- Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
- Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
- Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
- Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
- Twenty-year experience in liver surgery in metastatic colorectal patients: a case series study in Ukraine
- Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)
- Surgical treatment of pancreatic neoplasia in children: a single-centre retrospective analysis of short-term outcomes
- Localized endometrioid-associated clear cell carcinoma of the anterior abdominal wall: a case-report
- Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)
- The experience of arterial catheter and port placement for hepatic arterial infusion via laparotomic surgery: single-center study
- KEYNOTE-811: 6-year median follow-up of pembrolizumab plus trastuzumab and chemotherapy for previously untreated advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.